Scientists from the Institute of Biochemistry and Cell Biology (SIBCB) of the Chinese Academy of Sciences have identified a molecular “brake” for inflammation. Their results, published in Nature Immunology, could lead to new anti-inflammatory drugs or treatments for inflammation-driven cancers. Innate immunity is the first line of defense against pathogens. After detecting pathogen-associated molecular patterns, Toll-like receptors (TLRs) initiate innate immune response via activating the adaptor molecule Tumor necrosis factor receptor associated factor 6 (TRAF6) to remove pathogens. However, excessive or prolonged inflammatory responses can cause severe host damage or even death, meanwhile chronic inflammation could lead to the development of tumors. The balance between inflammation and tolerance must be fine maintained. (Read More from Asian Scientist) |